14th August 2026

The Convergence of Regulatory, Environmental, and Patient-Centric Imperatives

As a critical supplier of affordable medicines to global markets, and the world’s third-largest pharma industry by volume, India’s pharmaceutical packaging sector faces significant pressure to produce solutions which serve multiple needs at once. From meeting international regulatory requirements to increasing demands around sustainability, these pressures are not cheap to address, especially if the solution is based in the integration of new technologies. But with packaging being responsible for an estimated 20% of the cost [1] of medical device or drug production, it’s a prime aspect of pharma production for modernisation.

The importance of pharmaceutical packaging goes far beyond information and protection; now, it now offers the final checkpoint for quality assurance before products reach patients. Whether through tamper-evidence features that detect unauthorised access, barrier properties that maintain stability throughout shelf life or information systems to enable supply chain traceability and patient education, these properties can make or break a product’s performance in the wider pharmaceutical market.

For manufacturers in India, many of whom operate in highly competitive generic markets with limited opportunities for differentiation, packaging innovation helps to create value and meet the evolving expectations of patients, regulators and global healthcare systems. The country’s Central Drugs Standard Control Organisation (CDSCO) continues to align its standards more closely with the rest of the world, but still needs to address localised requirements. So, how can Indian pharmaceutical packaging developers meet both sets of needs without disrupting production or revenue streams?

Serialisation, Track-and-Trace, and Anti-Counterfeiting Technologies

The introduction of mandatory serialisation for pharmaceutical products, put in place to address concerns around safety and supply chain visibility, have required significant investment in new equipment and data management systems to improve the quality control process. Following these new protocols is now a prerequisite for pharma organisations in India looking for access to the global marketplace, which not only requires time and energy to implement, but needs further oversight in data management, resource planning and validation protocols to ensure system reliability.

India's domestic track-and-trace regulatory framework remains under development, with the CDSCO issuing an expansion of Schedule H2 [2] QR-code and barcode requirements that would require unique product identifiers, aggregation hierarchies and centralised repository systems to enable supply chain verification for antimicrobials, narcotics, psychotropics, and anticancer drugs effective from at least July 2027. However, India’s export-side DGFT Track & Trace/DAVA system [3] has been withdrawn as of February 2025, shifting responsibility to CDSCO/MoHFW and destination-country rules. As it stands, the implementation timeline has experienced delays as regulatory authorities address stakeholders’ concerns around technical feasibility, infrastructure readiness and cost implications for India's diverse pharmaceutical manufacturing sector.

Tamper-evidence features are also differently regulated across different jurisdictions and encompass multiple approaches including breakable caps, sealed blister packaging, shrink bands and specialised closures which incorporate features that are destroyed or permanently altered upon opening. Choosing the most suitable tamper-evidence technologies means balancing security effectiveness, cost considerations, compatibility with existing packaging lines and patient accessibility, which is especially important for products geared towards elderly patients.

Sustainable Packaging Materials and Circular Economy Approaches

As sustainability becomes a critical consideration within the pharma sector, the industry is rolling out initiatives at all points of the supply chain in order to make materials and processes more environmentally friendly. From substituting materials for bio-based or recyclable alternatives to optimising designs to reduce material usage, packaging offers a valuable area for these efforts to be introduced.

However, these efforts are not without their challenges, particularly if they are to meet standards across international jurisdictions. Packaging must meet regulations around specific materials [4] and designs and ensure product stability, particularly for those medications which are temperature, moisture or light-sensitive. As more traditional packaging materials such as PVC are being phased out, much of the development now revolves around material innovation - creating renewable, biodegradable polymers such as bio-based polyethylene and PET, which has quickly become of India’s most widely-used bio-based materials for pharmaceutical applications.

Meanwhile, the rise in circular economy approaches puts an emphasis on closed-loop systems where materials are recovered, recycled and reintegrated into new packaging, in order to reduce waste generation. This process can often be challenging due to these materials’ relative complexity, and the more localised issues around limited recycling infrastructure for Indian manufacturers. However, with financial incentives being offered to organisations introducing circular economy principles to their supply chain, there is clear global support available to the companies with a serious commitment to making these infrastructural improvements.

Smart Packaging and Patient Adherence Technologies

There are increasing demands on modern pharmaceutical packaging to provide critical data to support the ongoing function of the supply chain, as well as ensuring patient adherence from the end user. This is implemented through smart technologies like NFC tags and time-temperature indicators, which provide additional authentication and information access to ensure that product quality remains uncompromised.

Time-temperature indicators are most commonly used for biologics and some small molecule drugs requiring cold chain storage and distribution. They incorporate chemical or enzymatic systems that change colour when a particular temperature threshold has been exceeded for an extended duration. This allows for enhanced cold chain monitoring, providing documentation to support quality decisions regarding products which have undergone temperature excursions. For Indian pharmaceutical companies who manufacture and export temperature-sensitive products to the global market, these packaging details are becoming increasingly important to implement in order to demonstrate cold chain integrity and meet customer quality expectations.

The integration of smart packaging technologies also creates opportunities to address medication non-adherence, [3] which is estimated to affect approximately 50% of patients with chronic conditions. Adherence packaging formats particular value for elderly patients managing multiple medications or patients with cognitive impairments which can affect their ability to manage medication. For example, blister packs with calendar markings, multi-compartment organizers and unit-dose packaging provide visual cues for patients, simplifying dosing regimens and reducing confusion around medication schedules.

Integrating Regulatory Standards and Quality Management

Pharmaceutical packaging must comply with comprehensive regulatory requirements, encompassing material specifications, design standards, labelling content and quality management systems to ensure consistent performance. The International Council for Harmonisation (ICH) provides guidance addressing stability testing and packaging selection, though regional standards are still the driving influence on packaging decisions. The ICH’s regulatory frameworks establish specifications for packaging materials, while quality management standards including ICH Q10 and ISO 15378 [4] establish systems ensuring packaging quality throughout product lifecycles.

Validating the processes and systems around pharmaceutical packaging requires manufacturers to provide documented evidence to demonstrate that their operations consistently produce packaging which meeting all specifications. Validation protocols typically encompass installation qualification to verify that equipment has been installed correctly, operational qualification to confirm performance under numerous operating conditions and performance qualification to demonstrate sustained performance during actual operations. They also address parameters including seal integrity for blister packs and bottles, label application accuracy, serialisation system performance and vision inspection system efficacy. These tests have only become more rigorous over time, so Indian regulators’ increased adoption of ICH standards will ultimately be beneficial to the country’s pharma industry as a whole, particularly for companies exporting their goods to international markets.

Industry Platforms Facilitating Packaging Innovation and Technology Assessment

The complexity of international requirements around pharmaceutical packaging and the rapid evolution of packaging technologies has created ongoing demand for industry platforms which can help level the playing field and encourage new connections and knowledge sharing to push the industry forward. Most notably, CPHI & PMEC India, [5] which takes place 23-26 November 2026 across Delhi and Greater Noida, offers a dual-event format which focuses on two key elements of the supply chain - medicine and machinery - for the global pharma industry to explore. With specialised exhibition areas dedicated to manufacturing, packaging, APIs and excipients among many others, pharmaceutical professionals can conduct comparative evaluations of packaging materials, equipment systems and integrated solutions, while engaging directly with the technical experts who can address specific considerations for local manufacturing environments.

Whether you’re looking for support with modernisation, seeking new approaches to validation, or simply interested in learning more about meeting industry best practice standards, you’ll find it at this gathering of the packaging technology ecosystem. For Indian pharmaceutical manufacturers navigating the convergence of serialisation mandates, sustainability imperatives and patient-centric design requirements, platforms like CPHI & PMEC India provide valuable forums for technology discovery, peer learning and relationship development with suppliers who can support comprehensive packaging modernisation initiatives.